tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Charmacy Pharmaceutical Reports Decline in Interim Revenue and Profit

Story Highlights
Charmacy Pharmaceutical Reports Decline in Interim Revenue and Profit

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) just unveiled an announcement.

Charmacy Pharmaceutical Co., Ltd. announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a decline in operating revenue by 8.18% to RMB 2,155,071,000 and a decrease in net profit attributable to shareholders by 18.72% to RMB 21,739,000 compared to the same period in 2024. This decline in financial performance reflects challenges in the market and may impact the company’s positioning and stakeholder interests.

More about Charmacy Pharmaceutical Co., Ltd. Class H

Charmacy Pharmaceutical Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on providing pharmaceutical products and services.

Average Trading Volume: 42,140

Technical Sentiment Signal: Sell

Current Market Cap: HK$629.6M

Find detailed analytics on 2289 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1